InvivoCrown, founded in 2021 in the Cambridge Science Park, UK, as a deep participant in immunology research, takes "Crowning Science" as its core philosophy and focuses on providing global researchers in the fields of immunology and oncology with high-purity, cost-effective, function-oriented in vivo-grade antibody solutions. Our team integrates cutting-edge technologies with pragmatist concepts. Led by a team of immunology experts from the University of Cambridge and with nearly 20 years of experience in antibody drug development, we have created a product matrix with both excellent performance and cost advantages – from classic immune checkpoint targets (such as PD1/PD-L1) to novel tumor microenvironment regulatory antigens. All antibodies undergo rigorous in vivo validation to ensure their stability and reliability in in vivo models.
As practitioners of the in vivo-grade antibody standard, we take "ultra-purity, low endotoxin, and no additives" as rigorous criteria: we achieve glycosylation homogeneity through a unique stable cell expression system, eliminate interference from preservatives and stabilizers, and maintain ultra-low endotoxin levels (<1 EU/mg) to avoid experimental errors from the source. This strict pursuit of quality makes each antibody a "standard for in vivo research" trusted by customers. We have covered both popular and emerging targets, supporting not only conventional immune checkpoint blockade (such as Anti-PD-1 monoclonal antibodies) but also providing customized development for personalized needs to help researchers accelerate breakthroughs in frontier fields such as CAR-T combination therapies and bispecific antibody drug research and development.
We believe that scientific progress requires "subtraction" – reducing redundant trial-and-error costs and complex validation processes. We advocate and practice the 3R principles (Replacement, Refinement, Reduction of animal experiments). InvivoCrown actively reduces production costs through an industry-leading cost-performance strategy, enabling research institutions to obtain preclinical-grade antibodies with better budgets and accelerate the transformation process from mechanistic exploration to drug development.
Currently, our products have served research institutions in over 30 countries worldwide. In the future, the team will continue to deepen its AI-driven antibody design platform, expand bispecific antibody and antibody-drug conjugate (ADC) pipelines, and provide more precise solutions for cancer treatment.
© 2021-2025 InvivoCrown Limited. All rights reserved.